This page shows results related to Alaway and Keratoconjunctivitis Sicca from the FDA Adverse Event Reporting System (AERS). The adverse event Keratoconjunctivitis Sicca has been reported to the FDA a total of 4 times for Alaway.
Learn More About Alaway Adverse EventsThe Proportional Reporting Ratio (PRR) for Alaway and Keratoconjunctivitis Sicca is 138. The chart below compares this proportional reporting ratio of Keratoconjunctivitis Sicca for drugs used in similar therapies to Alaway. The higher the proportional reporting ratio is, the more likely a drug is associated with Keratoconjunctivitis Sicca.
| Keratoconjunctivitis Sicca | |
| Alaway | 50 |
NOTE: The PRR metric is still in Beta testing by DrugCite and is intended for use by researchers only.
Of those reporting Keratoconjunctivitis Sicca, why were they taking Alaway?
| Off Label Use | 1 |
| Eye Allergy | 1 |
| Eye Pruritus | 1 |
| Keratoconjunctivitis Sicca | 1 |
Which medications reported to the FDA are most commonly associated with Keratoconjunctivitis Sicca?
| Accutane | 82 |
| Vioxx | 66 |
| Zometa | 55 |
| Aredia | 41 |
| Fosamax | 33 |
| Arimidex | 24 |
| Humira | 22 |
| Forteo | 19 |
| Alendronate Sodium | 18 |
| Byetta | 17 |
| Botox Cosmetic | 16 |
 Show More |
